Clinical use of crizotinib for the treatment of non-small cell lung cancer
Patrick J Roberts Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Absract: Discoveries over the last decade have fundamentally transformed the way we define lung cancer. Gone are the days of the simple binary classification system of non-smal...
Guardado en:
Autor principal: | Roberts PJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8dd0707422e54eee911749e60871090e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Crizotinib-induced immunogenic cell death in non-small cell lung cancer
por: Peng Liu, et al.
Publicado: (2019) -
Clinical and comparative utility of afatinib in non-small cell lung cancer
por: D'Arcangelo M, et al.
Publicado: (2014) -
The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
por: William Boland, et al.
Publicado: (2010) -
Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer
por: Peng Liu, et al.
Publicado: (2019) -
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
por: D'Arcangelo M, et al.
Publicado: (2013)